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Alex Murray, FRCP6, Carole Brewer, MD7, Caroline Pottinger, MD8, D. Gareth Evans, MD9,
Diana Eccles, MD10, EMBRACE1, Fiona Lalloo, MD11, Helen Gregory, MD12, Jackie Cook, MD13,
Jacqueline Eason, MD14, Julian Adlard, MD PhD15, Julian Barwell, MD16, Kai Ren Ong, MD17,
Lisa Walker, PhD18, Louise Izatt, PhD19, Lucy E. Side, MD20, M. John Kennedy, MB21,
Marc Tischkowitz, MD PhD22, Mark T. Rogers, MD23, Mary E. Porteous, MD24,
Patrick J. Morrison, MD25, Ros Eeles, MD PhD26, Rosemarie Davidson, MD27, Katie Snape, MD28,
Douglas F. Easton, PhD1,29 and Antonis C. Antoniou, PhD1
Purpose: BRCA1/BRCA2 predictive test negatives are proven
noncarriers of a BRCA1/BRCA2 mutation that is carried by their
relatives. The risk of developing breast cancer (BC) or epithelial
ovarian cancer (EOC) in these women is uncertain. The study
aimed to estimate risks of invasive BC and EOC in a large cohort of
BRCA1/BRCA2 predictive test negatives.
Methods: We used cohort analysis to estimate incidences,
cumulative risks, and standardized incidence ratios (SIRs).
Results: A total of 1,895 unaffected women were eligible for
inclusion in the BC risk analysis and 1,736 in the EOC risk analysis.
There were 23 incident invasive BCs and 2 EOCs. The cumulative
risk of invasive BC was 9.4% (95% confidence interval (CI) 5.9–15%)
by age 85 years and the corresponding risk of EOC was 0.6% (95% CI
0.2–2.6%). The SIR for invasive BC was 0.93 (95% CI 0.62–1.40) in
the overall cohort, 0.85 (95% CI 0.48–1.50) in noncarriers from
BRCA1 families, and 1.03 (95% CI 0.57–1.87) in noncarriers from
BRCA2 families. The SIR for EOC was 0.79 (95% CI 0.20–3.17) in the
overall cohort.
Conclusion: Our results did not provide evidence for elevated risks
of invasive BC or EOC in BRCA1/BRCA2 predictive test negatives.
Genet Med advance online publication 22 March 2018
Key Words: BRCA1/BRCA2; breast cancer; ovarian cancer;
predictive test negatives; risks
INTRODUCTION
Several breast and ovarian cancer susceptibility genes have
been identified to date. The most important genes in the
context of genetic counseling are BRCA1 and BRCA2, which
are associated with high risks of developing breast, ovarian,
and other cancers.1–5 Genetic testing for BRCA1 and BRCA2
has become an integral part of genetic counseling; the
results are used to inform women’s treatment or clinical
management options, which involve a combination of
screening, prophylactic surgery, and other risk reduction
strategies.6–11
BRCA1/BRCA2 predictive test negatives are individuals who
have been offered a predictive test for a specific BRCA
mutation that has been found in a biological relative, and then
found to be a noncarrier. Several studies have estimated the
risk of developing breast cancer (BC) and epithelial ovarian
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cancer (EOC) in these women, but estimates vary widely
across studies. Although the risks have generally been found
to be lower than those in BRCA1 and BRCA2 mutation
carriers, retrospective studies have estimated the risks of BC
to be two- to fivefold higher than the risk in the general
population.12,13 Estimates based on retrospective studies may
be overestimated if ascertainment is not correctly allowed for
in the analysis. The findings from the eight prospective
studies published to date have been conflicting. In five of
them, risk to noncarriers was not raised (0.52–0.95) (refs. 14–
18) while in three studies the estimated risks were
significantly increased (2.0–4.57) (refs. 19–21). An important
limitation in all these studies, however, was small sample size,
and as a result the point estimates have wide confidence
intervals. Data on EOC risks for BRCA1/BRCA2 predictive
test negatives are currently scarce and the only estimates
available are from retrospective studies.13,22
Here, we used data from a large prospective cohort of
BRCA1/BRCA2 predictive test negatives from the United
Kingdom to estimate the risks of developing BC or EOC.
MATERIALS AND METHODS
Subjects
The Epidemiological Study of Familial Breast Cancer
(EMBRACE) study is a prospective cohort study in the
United Kingdom and Republic of Ireland, aiming to
characterize cancer risks in BRCA1/BRCA2 mutation carriers
and their relatives. Individuals are eligible for inclusion in
EMBRACE if they (i) carry a pathogenic mutation in BRCA1
or BRCA2, (ii) are noncarriers in families with a pathogenic
BRCA1 or BRCA2 mutation, or (iii) are potential carriers but
opt not to undergo a predictive genetic test. Recruitment is
organized through regional cancer genetics centers, generally
close to the time of genetic testing. Recruitment commenced
in 1997 and includes both women and men. The cohort
includes individuals with or without personal history of
cancer; all participants complete a baseline questionnaire that
includes information on BC and EOC risk factors and medical
history. The EMBRACE study was approved by the former
Anglia and Oxford Medical Research and Ethics Committee
(North West Anglia Health Authority, Peterborough, United
Kingdom), now East of England–Cambridge South Research
Ethics Committee (Nottingham, United Kingdom).
Only noncarrier women were eligible for inclusion in the
present study. Information on date and cause of death, and
cancer diagnoses, was obtained through linkage with the
Health and Social Care Information Centre for England and
Wales, and with the National Health Service Central Register
for Scotland. For the purpose of the study, the last record
linkage was performed on 15 December 2015. The end of
follow-up was set as 15 July 2015 to ensure that any cancer
diagnoses by this date were likely to have been reported at the
time of the record linkage.
Cancer risks for BRCA1/BRCA2 predictive test negatives
were estimated separately for incident invasive BC and
incident EOC. Women were eligible for inclusion in the
analysis if they had not been diagnosed with cancer, other
than nonmelanoma skin cancer, before the date at the
baseline questionnaire (study recruitment). For the estimation
of BC risk, participants were ineligible if they had already
undergone risk-reducing bilateral mastectomy at recruitment.
In estimating EOC risk, participants were ineligible if they had
undergone risk-reducing salpingo-oophorectomy (RRSO) or
bilateral salpingectomy (because noncarriers in EMBRACE do
not complete follow-up questionnaires after study recruit-
ment, information on prospective prophylactic surgeries
occurring after the baseline questionnaire date was not
available). Women were followed from baseline until the
first of (i) death, (ii) a diagnosis of a cancer other than
nonmelanoma skin cancer, (iii) attained age 85 years, or (iv)
15 July 2015. For the BC risk estimation, only women
diagnosed with an incident invasive BC were assumed to be
affected (i.e., noninvasive BCs were ignored but censored as
unaffected at diagnosis) and for the EOC analysis only women
diagnosed with an EOC were assumed to be affected.
Statistical analysis
Annual incidences of invasive BC and EOC per 1,000 person-
years were estimated for the age intervals 18–24, 25–34, 35–
44, 45–54, 55–64, 65–74, and 75–84 using standard cohort
analysis. Kaplan–Meier analysis was used to estimate the
cumulative risks. The probability of experiencing the event of
interest up to a given time-point was calculated as 1−Kaplan-
Meier estimate of the survival probability. Differences in
cancer risks between members of BRCA1 families and
members of BRCA2 families were assessed using Cox
regression. The hazard ratio was defined as the ratio between
the hazard function at age t for noncarriers from BRCA2
families and the hazard function at age t for noncarriers from
BRCA1 families. To account for possible variation in risk due
to year of birth (i.e., cohort effect), the analysis was adjusted
for year of birth using a categorical variable based on the
observed quartiles (1922 to 1953, 1954 to 1963, 1964 to 1972,
1973 to 1995).
We assessed the difference between the estimated incidence
rates of invasive BC and EOC in the sample under study and
the corresponding incidence rates in a reference population
by estimating the standardized incidence ratio (SIR). A SIR is
the ratio between the number of observed incident cases and
the number of expected incident cases in the study population
over the period of observation. For this purpose, we used the
population incidences for England23 and assumed they also
apply to women recruited from Scotland and Wales. Expected
cases were calculated by applying the calendar period–
specific, age-specific, and cancer-specific incidences for
England to the eligible sample of noncarriers. These rates
were available from 1998 to 2014. Rates for 1998 and 2014
were assumed to apply for the years 1997 and 2015,
respectively. To allow for the fact that multiple individuals
from the same family may be included in the analyses robust
standard errors were calculated by clustering on family.24
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RESULTS
The process of generating the eligible sets for inclusion in
the BC and EOC analyses are described in the appendix
(Supplementary Figures S1 and S2 online). Table 1
summarizes the eligible cohort characteristics.
Risk of invasive BC
Among 1,895 BRCA1/BRCA2 predictive test negatives eligible
for inclusion in the BC analysis, 23 incident invasive BCs
occurred, 12 in women from BRCA1 families and 11 in
women from BRCA2 families. The estimated incidences,
cumulative risks, and SIRs are shown in Table 2. The crude
incidence rate of invasive BC in the overall sample was
estimated to be 1.72 per 1,000 person-years (95% confidence
interval (CI) 1.16–2.66). The incidence rate increased rapidly
at young ages up to age 45 but remained relatively constant
after that age, ranging from 2.33 to 3.04 per 1,000 person-years.
The estimate was similar when analysis was restricted to
individuals of European ancestry (1.74/1,000 person-years,
95% CI 1.17–2.70). The incidence rate in members of BRCA2
families (1.95/1,000 person-years, 95% CI 1.11–3.79) was
slightly, but not significantly (p value 0.58), higher than the
rate in members of BRCA1 families (1.55/1,000 person-years,
95% CI 0.90–2.92). After adjustment for birth cohort, the
hazard ratio estimate for members of BRCA2 families versus
members of BRCA1 families was 1.20 (95% CI 0.53–2.70,
Wald test p value= 0.6). The SIR estimate for invasive BC was
0.93 (95% CI 0.62–1.40). In the age-specific analysis the
highest SIR was estimated for age group 45–55 (SIR= 1.30,
95% CI 0.72–2.35), but SIRs were estimated to be o1 for all
other age groups (range: 0.35–0.89). There was no apparent
trend in the SIRs with age. The SIR was estimated to be 0.85
(95% CI 0.48–1.50) for members of a BRCA1 family with the
highest SIR estimated for age group 65–75 (SIR= 1.56, 95%
Table 1 Descriptive summary of the cohorts in which risks were calculated, separately for invasive BC and EOC
Eligible set for invasive BC analysis Eligible set for EOC analysis
Overall BRCA1a BRCA2a Overall BRCA1a BRCA2a
Sample, N (%) 1,895 1,042 (55) 849 (45) 1,736 939 (54) 793 (46)
Mean age at questionnaire (SD) 45.1 (13.1) 44.6 (13.1) 45.6 (13) 44.2 (13.1) 43.5 (13) 45.1 (13.1)
Mean follow-up in years (SD) 7.1 (4.5) 7.4 (6.6) 6.6 (4.3) 7.0 (4.5) 7.3 (4.7) 6.6 (4.3)
Failures 23 12 11 2 0 2
Mean age at failure (SD) 57.2 (8.8) 60.5 (9.7) 53.6 (6.2) 50.5 (8.0) — 50.5 (8.0)
Ethnicity (%)
Unknown 1 (0) 0 1 (0) 1 (0) 0 1 (0)
White 1,810 (96) 982 (94) 824 (97) 1,658 (95) 885 (94) 769 (97)
Indian 5 (0.3) 4 (0.4) 1 (0.1) 5 (0.4) 4 (0.5) 1 (0.1)
Black-Caribbean 3 (0.2) 3 (0.3) 0 3 (0.2) 3 (0.3) 0
Ashkenazi Jewish 47 (2) 34 (3.4) 13 (1.8) 45 (3) 32 (3.4) 13 (1.8)
Bangladeshi 1 (0) 1 (0.1) 0 1 (0) 1 (0.1) 0
Pakistani 3 (0.2) 2 (0.2) 1 (0.1) 3 (0.2) 2 (0.2) 1 (0.1)
Black other 5 (0.3) 5 (0.5) 0 4 (0.3) 4 (0.5) 0
Chinese 1 (0) 0 1 (0.1) 0 0 0
Other 19 (1) 11 (1.1) 8 (0.9) 16 (0.9) 8 (1) 8 (1)
Number of families (%) 1,602 887 (55) 711 (45) 1,488 812 (55) 672 (45)
Families by number of noncarriers (%)
1 1,381 (86) 767 (86) 610 (86) 1,300 (87) 714 (88) 582 (88)
2 179 (11) 98 (11) 81 (11) 152 (11) 80 (10) 72 (11)
3 25 (2) 14 (2) 11 (1.6) 24 (1.5) 11 (1.3) 13 (0.3)
4 14 (1) 6 (0.8) 8 (1.3) 9 (0.5) 5 (0.5) 4 (0.6)
5 1 (0) 1 (0.1) 0 1 (0) 1 (0.1) 0
6 0 0 0 0 0 0
7 0 0 0 1 (0) 1 (0.1) 0
8 1 (0) 1 (0.1) 0 0 0 0
9 0 0 0 0 0 0
10 0 0 0 0 0 0
11 0 0 0 0 0 0
12 1 (0) 0 1 (0.1) 1 (0) 0 1 (0.1)
BC, breast cancer; EOC, epithelial ovarian cancer. aIn four individuals family identification number and family mutation were missing. In reference to familial clustering,
these individuals were assumed to be independent. No assumptions were made on family mutation; therefore, in the stratified analysis by family mutation, these indivi-
duals were not considered.
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CI 0.59–4.16) and 1.03 (95% CI 0.57–1.87) for relatives of
BRCA2 mutation carriers with the highest SIR occurring for
ages 45–55 (SIR= 1.85, 95% CI 0.88–3.87) (Table 2). The risk
of developing invasive BC in the pooled sample was estimated
to be 3% (95% CI 1.7–5.3%) by age 55 years and 9.4% (95% CI
5.9–15%) by age 85 years (Figure 1). When analysis was
restricted to members of BRCA1 families, the cumulative
risk of invasive BC was estimated to be 1.8% (95% CI 0.7–
4.8%) by age 55 and 11% (95% CI 5.6–19%) by age 85. For
members of BRCA2 families, the risk of developing invasive
BC was 4.5% (95% CI 2.3–8.8%) by age 55 and 7.7% (95% CI
4.2–14%) by age 85 (Supplementary Figure S3 online).
Sensitivity analyses, after excluding women with bilateral
oophorectomy, excluding the first year of follow-up or by
including in situ BCs yielded similar results (sensitivity
analyses described in the appendix (Supplementary Table S1
online)).
Risk of EOC
In the cohort of 1,736 noncarriers eligible for the EOC
analysis, two incident EOCs were observed, both in
individuals from BRCA2 families, with ages at diagnosis
44.8 and 56.1 years. The crude EOC incidence rate in the
overall sample was 0.16 per 1,000 person-years (95% CI 0.03–
1.66). The estimated SIR for EOC was 0.79 (95% CI 0.20–
3.17) for all age groups. With only two incident EOCs, SIR
estimates by age group and by family mutation were either
not possible or associated with wide confidence intervals.
They are not therefore reported. The estimated absolute risk
of EOC in noncarriers was 0.6% (95% CI 0.2–2.6%) by age
85 years. In a sensitivity analysis that included women with a
prior BC diagnosis in the eligible cohort, results were
unchanged (Supplementary Material online).
DISCUSSION
This is the largest prospective cohort study of BRCA1/BRCA2
predictive test negatives to date. We found no evidence of an
increased BC or EOC risk in relatives of BRCA1 or BRCA2
mutation carriers. The BC risk estimates were not influenced
by the inclusion of individuals with prior bilateral salpingo-
oophorectomy. When the four noninvasive prospective BCs
were also considered as events, to rule out the possibility that
some cancers were being wrongly excluded, the SIR estimates
were similar. Similarly, after censoring individuals at an
earlier date (15 June 2014) to allow for possible risk
underestimation due to delayed cancer notification, results
were unchanged.
Early clinical recommendations on hereditary BC and EOC
recommended standard surveillance for BRCA1/BRCA2
predictive test negatives.25 In 2013, the United States
Preventive Services Task Force issued a recommendation
reiterating that noncarriers were at population risk.26,27
According to the National Institute for Health and Care
Excellence guidelines,6 women at population risk should be
given standard surveillance and discussion of any further risk-
reducing intervention would not be appropriate. If, however,
BRCA1/BRCA2 predictive test negatives are at increased risk
of developing BC, as recently suggested,19–21 the recommen-
dations for women at moderate to high risk of developing BC
may apply.
In five of the eight prospective studies published to date, the
estimated SIR for BC was in line with our results (range of
SIRs = 0.52–0.95) (refs. 14–18). In three studies a significant
two- to fivefold increased risk of BC was reported compared
with population risks, but there were inconsistencies between
these studies.19–21 Evans et al.19 found a statistically significant
increased risk only for relatives of BRCA2 mutation carriers,
while Vos et al.21 found a statistically significant increased risk
only for relatives of BRCA1 mutation carriers. Both studies
only included first-degree relatives of known mutation
carriers. The authors argued that common genetic variants,
which modify risks in BRCA1/BRCA2 carriers, also may
modify risk in noncarriers. These predisposing variants would
be more likely to segregate in families with multiple affected
individuals, such as those ascertained in genetics clinics.
Korde et al.17 and Nielsen et al.,18 however, did not find an
increase in the risk of BC for BRCA predictive test negatives
who were first-degree relatives of mutation carriers. A
limitation of all these studies was the small sample size (none
included more than 21 BC cases). In the present study we
were not able to restrict analysis to only first-degree relatives
of known mutation carriers because the exact familial
relationships were not available. Similarly, we were not able
to investigate the variation in risk by family history of cancer.
Korde et al.17 reported a nonsignificant increase in the risk of
BC for noncarriers with an affected first-degree relative. In
Harvey et al.16 the estimated SIR of BC in predictive test
negatives without affected relatives in the parental lineage
not associated with the BRCA mutation was 0.48, albeit
statistically not significant.
Only a few published studies provided a SIR for EOC (range
of SIRs reported: 0–4.6) (refs. 13,22) but all were based on
retrospective studies. Three prospective studies15,20,21 aimed
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Figure 1 Kaplan–Meier plot for the risk of invasive breast cancer in
the combined sample of noncarriers from families with BRCA1 and
BRCA2 mutations. CI, confidence interval.
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to estimate a SIR for EOC. In Domchek et al.15 and Rowan et
al.20 no events occurred during the follow-up, while Vos et
al.21 reported two EOCs but the corresponding SIR was not
provided. This is the first study to estimate a SIR for EOC
based on a prospective cohort, but the confidence intervals
were wide due to the small number of events.
The sample size of this study is larger than previous studies
and the confidence limits are correspondingly narrower.
Nonetheless, when considering BC risk estimates by age
group and family mutation, caution is needed due to the
relatively small number of events in each stratum. Because
this is a prospective cohort, estimates are less likely to be
prone to ascertainment or reporting biases, usually associated
with retrospective or historical cohort studies.
Limitations of this study include the following:
1. The SIRs were calculated using incidences from England,
but EMBRACE noncarriers were also recruited in
Scotland and Wales. Age-specific estimates for these
countries were not readily available; however, data from
previous periods indicate that the incidence rates are
similar amongst countries. Moreover, the large majority
of study participants (83.3%) were from clinics based in
England.
2. Surgeries unrelated to cancer diagnoses prior to recruit-
ment were not verified through surgical records, but bias
due to misreporting or underreporting was probably
small given the life-changing sexual and physical impact
of risk-reducing surgery.28–30
3. No information on prophylactic surgeries after recruit-
ment was available. Such surgeries are unlikely in women
testing negative for mutations; however, if risk-reducing
surgeries are more frequent in the noncarriers within
families with BRCA1 and BRCA2 mutations compared
with the general population this may lead to an
underestimation of the SIR. In an approximate calcula-
tion, assuming the same proportion (i.e., 0.88%) of
bilateral mastectomies in the prospective cohort as in the
retrospective data, 17 such procedures would be
expected. In the unlikely event that all these individuals
would have developed invasive BC if they had not
undergone surgery, the observed/expected ratio would
have been 1.61 (95% CI 1.18–2.2). In the retrospective
data, 5.4% of noncarriers from BRCA1 families had
undergone bilateral oophorectomy with or without
bilateral salpingectomy, compared with 3.3% of non-
carriers from BRCA2 families, possibly reflecting differ-
ential counseling toward risk-reducing surgery when a
BRCA1 mutation segregates in the family. In the current
sample, 98% of noncarriers from BRCA1 families who
underwent bilateral oophorectomy (or bilateral salpin-
gectomy) at baseline had the procedure before genetic
testing, whereas only 3% underwent RRSO after
notification of the negative result. If the uptake of RRSO
(after notification of mutation carrier status) was similar
in the prospective cohort, this may have led to some
underestimation of the EOC SIR for relatives of BRCA1
mutation carriers and in the overall sample. However,
the size of these biases is most likely small because risk-
reducing bilateral mastectomy and RRSO after the
disclosure of a negative result are less likely.
4. The noncarrier’s degree of relationship with the muta-
tion carrier and cancer family history were not available.
Although women were ascertained through clinical
genetics centers and most would have come from high-
risk families, ascertainment criteria with respect to
family history can vary. Therefore, it is not possible to
rule out that risk in noncarriers may be increased if
multiple family members or first-degree relatives are
affected.
5. No information on the date of the most recent
screening mammogram or breast magnetic resonance
imaging was available. If BRCA1/BRCA2 predictive test
negatives with a normal breast imaging close to the
genetic test discontinue surveillance following the
notification of noncarrier status, they may be subject to
a reverse lead time effect if they are diagnosed with a BC
and this may lead to some underestimation of the risk.
We investigated this by calculating the BC incidence in
3-year intervals following the genetic test. Although
there was a suggestion of a higher BC incidence rate
between 3 and 6 years following the genetic test
compared with the initial years, the differences were
not significant. Larger sample sizes will be required to
clarify this potential bias.
6. Although this is the largest prospective study, the mean
follow-up time in the cohort was still relatively short (7.1
years) and longer follow-up will be required to
investigate the risks at older ages with more precision.
Based on the confidence interval of the invasive BC SIRs, a
1.5-fold increase in risk in noncarriers from BRCA1 families
and a 1.9-fold increase in noncarriers from BRCA2 families
cannot be ruled out. Translating these SIRs to lifetime risk
yields an upper bound of risk of ~ 17% to age 80 years for
relatives of BRCA1 mutation carriers and ~ 20% to age 80
years for relatives of BRCA2 mutation carriers, based on UK
general population incidences.31 Hence, even at the upper
bound of the 95% CI, BRCA1/BRCA2 predictive test negatives
would not be classified as being at high risk of developing
invasive BC according to the National Institute for Health and
Care Excellence guidelines.6
The familial aggregation of BC is known to be determined
by other factors, including multiple common genetic variants,
in addition to BRCA1 and BRCA2 mutations. Thus, one
would predict that BRCA1/BRCA2 predictive test negatives in
cohorts such as the present study, who have a family history
of BC and are hence more likely to carry other predisposing
variants, would still be at increased risk relative to general
population. We therefore investigated whether the present
estimates are consistent with predictions given by the Breast
and Ovarian Analysis of Disease Incidence and Carrier
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Estimation Algorithm (BOADICEA) model, which models
the familial aggregation of BC in terms of BRCA1/2 mutation
status and a residual polygenic component. We computed the
predicted lifetime risk of BC for a 20-year-old true negative,
with two different family histories: (i) a mutation-positive
mother diagnosed with BC at age 50 years, and (ii) a mother
and maternal grandmother both diagnosed with BC at age 50
and carrying a mutation. The predicted BC risks to age 80
years in these two scenarios were 12 and 13% for a BRCA1
positive family, and 14 and 15% for a BRCA2 positive family.
These women would be classified as at near population risk
according to BOADICEA. Nevertheless, the predicted risks
are somewhat higher than the point estimates in the present
study, but within or close to the upper confidence interval
bounds of the estimated cumulative risks. These observations
suggest that the BOADICEA model may overestimate slightly
the risks to individuals with a negative predictive test.
However, larger sample sizes will be required to resolve this
issue: if the true risks were in line with those predicted by
BOADICEA, a prospective study with at least 100 events
would be required to provide sufficient statistical power.
Our results suggest that BRCA1/BRCA2 predictive test
negatives can be classified as being at near-population risk as
defined by the National Institute for Health and Care
Excellence guidelines.6 Therefore, it would not be appropriate
to offer risk-reducing bilateral mastectomy and RRSO to these
individuals. In practice a proportion of women undergo
preventative surgery based solely on the family history. Based
on these data, predictive genetic testing of female relatives of a
known BRCA1/BRCA2 mutation carrier is strongly beneficial
in terms of avoiding unnecessary surgical procedures for those
found to be BRCA1/BRCA2 negative. Standard surveillance
may be offered, unless personal risk factors warrant further
consideration such as strong family history of cancer in the
parental lineage not associated with the known mutation or
history of lobular carcinoma in situ or atypical ductal
hyperplasia.32,33
SUPPLEMENTARY MATERIAL
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